What is it about?
Hypoxia-activated prodrugs are drugs that are activated by low oxygen regions in the body. They work well in theory, but have trouble in practice because of variable hypoxia in patients. Antiangiogenic agents are drugs that attack tumour blood vessels, and similarly work well in theory, but struggle in practice. However, combining these drugs and administering them using drug-carrying nanoparticles can produce beneficial results. We show this using a mathematical modelling approach.
Featured Image
Photo by Roberto Sorin on Unsplash
Why is it important?
We use mathematical modelling techniques to show that a novel drug combination, and particular administration method, can lead to an improvement in drug efficacy over administering the drugs separately. This can give these two classes of anticancer drug a new use case and improve outcomes for patients.
Perspectives
This article was a great opportunity to showcase how mathematical models can be used to discover novel therapeutic strategies. It is interesting to generate hypotheses which are testable by experiment.
Cameron Meaney
Read the Original
This page is a summary of: In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery, PLoS Computational Biology, May 2020, PLOS,
DOI: 10.1371/journal.pcbi.1007926.
You can read the full text:
Contributors
The following have contributed to this page
